Assessing Axi-Cel in R/R LBC Lymphoma in ZUMA-7: Frederick Locke, MD

This content originally appeared on our sister site, OncLive.

OncLive spoke with Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, and co-leader, Immuno-Oncology, Moffitt Cancer Center, to learn more about the results of the phase 3 ZUMA-7 trial (NCT03391466) in patients with large B-cell lymphoma ​(LBCL).

Data from the ZUMA-7 trial were presented at the 2021 ASH Annual Meeting & Exposition. The trial's primary endpoint is event-free survival (EFS), defined as time from randomization to the earliest date of disease progression including death due to any cause or commencement of different anti-lymphoma therapy.

Data demonstrated that over 90% of patients randomized received CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta), whereas about 30% of patients received a definitive autologous hematopoietic stem cell transplant, Locke explained.

The findings from the study demonstrated a median EFS of 8.3 months with axi-cel vs 2 months with standard of care in patients with relapsed/refractory LBCL, Locke continues. Notably, the 24-month EFS rate was 40.5% compared with 16.3%, respectively. This means that at 2 years after randomization, over 40% of patients who received axi-cel arm did not require additional therapy and remained in remission, Locke concludes.

For more coverage of ASH 2021, click here.